Theravance Biopharma Inc
TBPHHealthcare|Biotechnology|USA
$16.94
-0.06 (-0.32%)
Tangible Book
$5.64
Graham Number
$11.62
About
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Stock Price
+47.8%(1Y)
Pipeline Summary
74 total trials39
Phase 1
24
Phase 2
11
Phase 3
3
Phase 4
Completed: 65Terminated: 7Active: 1Recruiting: 1
Active Trials (2)
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension
Phase 3Active
Enrollment: 102 participants
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
NCT07133880COPD (Chronic Obstructive Pulmonary Disease)
Phase 4Recruiting
Enrollment: 72 participants
BioScore
4/10
Cautious
Ownership
Recent Insider Trades
Samaha EliSELL
2026-07-01336,697 shares @ $17.2
Farnum RhondaSELL
2026-06-1513,314 shares @ $16.39
Farnum RhondaSELL
2026-03-1631,067 shares @ $13.96
Farnum RhondaSELL
2025-12-0331,067 shares @ $18.75
BROSHY ERANSELL
2025-11-2629,501 shares @ $20
Recent News
2026-07-10 00:00:03
2026-07-09 19:00:03
2026-07-07 12:41:48
2026-06-29 18:59:19
2026-06-29 18:00:13
Data last updated: Jul 13, 2026, 12:49 PM